Mednet Logo
HomeQuestion

How do you manage patients who develop de novo or recurrent skin cancers (SCC or BCC) while on lenalidomide?

1 Answers
Mednet Member
Mednet Member
Medical Oncology · Winship Cancer Institute of Emory University

The most common hematologic malignancies in patients who have undergone stem cell transplantation and then lenalidomide maintenance are acute myeloid leukemia, myelodysplastic syndrome, and rarely acute lymphocytic leukemia (Palumbo A, Lancet Oncol, 2014, PMID 24525202 & Aldoss I, Leukemia, 2019).

Le...

Register or Sign In to see full answer

How do you manage patients who develop de novo or recurrent skin cancers (SCC or BCC) while on lenalidomide? | Mednet